Lipocine (LPCN) Competitors $3.15 -0.08 (-2.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.16 +0.00 (+0.16%) As of 08/1/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPCN vs. PMVP, QNTM, AVTX, BRNS, MNOV, CELU, ASRT, INCR, IRD, and GNTAShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include PMV Pharmaceuticals (PMVP), Quantum Biopharma (QNTM), Avalo Therapeutics (AVTX), Barinthus Biotherapeutics (BRNS), MediciNova (MNOV), Celularity (CELU), Assertio (ASRT), InterCure (INCR), Opus Genetics (IRD), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry. Lipocine vs. Its Competitors PMV Pharmaceuticals Quantum Biopharma Avalo Therapeutics Barinthus Biotherapeutics MediciNova Celularity Assertio InterCure Opus Genetics Genenta Science PMV Pharmaceuticals (NASDAQ:PMVP) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations. Is PMVP or LPCN more profitable? Lipocine's return on equity of -26.68% beat PMV Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PMV PharmaceuticalsN/A -32.54% -29.59% Lipocine N/A -26.68%-24.77% Do analysts prefer PMVP or LPCN? PMV Pharmaceuticals currently has a consensus price target of $5.50, suggesting a potential upside of 292.86%. Lipocine has a consensus price target of $9.00, suggesting a potential upside of 185.71%. Given PMV Pharmaceuticals' higher possible upside, research analysts clearly believe PMV Pharmaceuticals is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lipocine 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in PMVP or LPCN? 90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher earnings & valuation, PMVP or LPCN? Lipocine has higher revenue and earnings than PMV Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMV PharmaceuticalsN/AN/A-$58.71M-$1.18-1.19Lipocine$11.20M1.50$10K-$1.02-3.09 Does the media prefer PMVP or LPCN? In the previous week, PMV Pharmaceuticals' average media sentiment score of 1.70 beat Lipocine's score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment PMV Pharmaceuticals Very Positive Lipocine Neutral Which has more risk and volatility, PMVP or LPCN? PMV Pharmaceuticals has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. SummaryPMV Pharmaceuticals beats Lipocine on 6 of the 11 factors compared between the two stocks. Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.28M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-3.098.9728.7823.81Price / Sales1.50437.65372.2066.04Price / CashN/A157.7635.4557.96Price / Book0.804.838.275.54Net Income$10K$31.62M$3.25B$259.28M7 Day Performance-8.43%-5.28%-3.70%-4.64%1 Month Performance1.29%4.38%4.34%4.41%1 Year Performance-36.49%-2.49%25.90%17.95% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine2.6247 of 5 stars$3.15-2.5%$9.00+185.7%-38.0%$17.28M$11.20M-3.0910Positive NewsUpcoming EarningsPMVPPMV Pharmaceuticals3.5313 of 5 stars$1.51+7.1%$5.50+264.2%-11.9%$73.25MN/A-1.2850Positive NewsUpcoming EarningsQNTMQuantum BiopharmaN/A$24.88-1.1%N/AN/A$73.12MN/A-1.56N/AGap DownAVTXAvalo Therapeutics3.0481 of 5 stars$6.58-1.6%$30.00+355.9%-28.6%$72.44M$440K0.0040News CoverageBRNSBarinthus Biotherapeutics2.2684 of 5 stars$1.55-13.4%$6.25+303.2%-7.1%$72.21M$14.97M-0.95107Positive NewsUpcoming EarningsGap DownMNOVMediciNova2.7077 of 5 stars$1.45-0.7%$7.00+382.8%+8.3%$71.61M$1M-6.3010News CoverageUpcoming EarningsGap UpHigh Trading VolumeCELUCelularity0.2161 of 5 stars$3.29+11.1%N/A-1.0%$70.89M$54.22M-1.24220News CoverageUpcoming EarningsAnalyst UpgradeASRTAssertio1.7156 of 5 stars$0.73-2.0%$2.63+262.1%-48.4%$70.88M$124.96M-2.2720News CoverageUpcoming EarningsINCRInterCureN/A$1.51-2.6%N/A-32.1%$70.64M$66.28M0.00350Gap UpIRDOpus Genetics1.1956 of 5 stars$1.20+1.7%$7.33+511.1%N/A$70.40M$10.99M-0.5714GNTAGenenta Science1.8095 of 5 stars$3.75-0.8%$25.00+566.5%-13.5%$69.14MN/A0.007Short Interest ↑ Related Companies and Tools Related Companies PMVP Alternatives QNTM Alternatives AVTX Alternatives BRNS Alternatives MNOV Alternatives CELU Alternatives ASRT Alternatives INCR Alternatives IRD Alternatives GNTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPCN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPCN Stock Alerts